Sec. 51.0004.  REIMBURSEMENT REQUIREMENTS; NOTICE.  (a)  A reimbursement under the program must:
(1)  be reviewed and approved by the institutional review board associated with the cancer clinical trial for which the reimbursement is provided; and
(2)  comply with applicable federal and state laws.
(b)  The independent, third-party organization operating the program is not required to obtain approval from an institutional review board on the financial eligibility of a subject who is medically eligible for the program.
(c)  The independent, third-party organization operating the program shall provide written notice to a subject on:
(1)  the nature and availability of the ancillary financial support under the program; and 
(2)  the program's general guidelines on financial eligibility.
Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. 3147), Sec. 2, eff. September 1, 2019.
Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. 3607), Sec. 21.001(53), eff. September 1, 2021.